Category Archives: Suboxone Clinics

Methadone Maintenance For Opioid Treatment

methadone-and-opioid-treatmentOpioid Treatment is a category that includes several different interventions or approaches relating to opioid use disorders. People sometimes mistake opioid treatment for “opioid detox” when they are technically two different processes.

Opioid detox refers to the process of helping an opioid addicted individual discontinue their use of opioids and be medically monitored as the body withdraws from them. In a supervised setting, a person is typically assisted through a short-term opioid detox (3-10 days) by the administration of various medications used to manage withdrawal symptoms like clonidine (to guard against high blood pressure), vistaril (to reduce nausea and anxiety), and even buprenorphine (to minimize the severity of the opioid withdrawal process).

There are also variations on an opioid detox referred to as a taper. A taper often occurs on an outpatient basis and involves a more gradual reduction in dosage of either methadone or buprenorphine (suboxone) over time. This taper may take as long as 90 days and allows the individual to adjust more comfortably due to the slower, milder reduction in dosage that occurs over a coarse of weeks or months.

Maintenance is the term which refers to maintaining an individual for a significant period of time on either methadone or buprenorphine (suboxone) to allow for stabilization on the opioid replacement medication. Since opioid addiction introduces dramatic brain chemistry changes in conjunction with strong physical dependency and cravings for opiates, many people find that they need a substantial period of stabilization on methadone in order to have a realistic chance at building a personal recovery. Numerous individuals have decided that they will utilize methadone for only a few weeks with the intention of tapering off of it very quickly. This strategy is prone to failure and tends to end in dramatic relapses back to heroin and other illicit opioids.

Methadone maintenance for most opioid-addicted persons involves receiving methadone for a year or more. This length of time dramatically raises the probability of successful physical stabilization and necessary thinking, behavior, and lifestyle changes which lead to long-term drug abstinence and sustained, productive living. Put very simply, when people attempt to rush through the process of stabilization & recovery, they sabotage their chance of experiencing real success. For that reason, maintenance is a therapeutic process which should be regarded as a one year commitment or longer, and tapering off of methadone or buprenorphine should not be rushed. Bear in mind that not all individual situations are exactly the same and there are unique exceptions.

There are many different factors that play into how long a person needs to remain on methadone or suboxone maintenance. This is highly individualized depending on the length and severity of one’s opioid abuse history, one’s present medical status and general state of health, the availability of social & emotional supports, and the presence of any co-occurring psychiatric disorders like depression.

There is considerable misinformation about methadone tapering and a bit of fear-mongering that often occurs around the topic. People that generally taper successfully off of methadone or suboxone are individuals that have invested time in counseling and personal recovery growth, and who have developed a good working relationship with their doctor or treatment staff. These individuals approach tapering as a gradual goal and are allowed to halt or slow down their taper as needed. This allows their body time to adapt to the somewhat lower dosage. It also allows them to proceed slowly and carefully such that any anxiety or fears can be successfully identified and managed.

Choosing The Right Direction: Detox – Methadone – Suboxone

Canadian Press Publishes Article on Benefits of Methadone

canadian-methadone-clinicsFurther validating the merits of opioid treatment using methadone is a recent article by The Canadian Press outlining the findings of Canada’s Medical Health Officer in British Columbia, Dr. Perry Kendall.

Dr. Kendall’s report documents that individuals in opioid substitution therapy are twice as likely to survive compared to those who obtain opioids illegally on the street. Those in opioid addiction therapy were also found to be much more cost effective to society (about $4200 per year for treatment) compared to those with untreated addictions whose costs are estimated to be $45,000 per year collectively in health complications, law enforcement involvement, and other social problems such as loss of income.

The province of British Columbia is currently treating over 15,000 residents for opioid addiction. Their health minister, Terry Lake, is quoted as saying that he was encouraged by the findings in the report and that he knows opioid substitution therapy is not only saving lives, but equates to significant savings for the Canadian healthcare system and society.

In a related story, youth struggling with opioid addiction are being helped in Canada by the increased availability of suboxone. Sean Morrison of the Strengths youth addiction services discussed the benefit that suboxone offers in eliminating opioid withdrawal symptoms and cravings so that young people can stabilize and focus more quickly on addiction recovery goals.

While opposition is still present in the USA from certain groups regarding the establishment of methadone treatment services near their community, the medical community and various treatment providers are increasingly able to demonstrate good outcomes with methadone and suboxone supported services. The science of addiction treatment using methadone and suboxone is powerful & compelling – thus legitimizing its increased availability to people who need it. Simply put, opioid substitution therapy saves lives and produces irrefutable medical and psychological benefits for those people struggling in addiction.

Behavioral Health Group (BHG) Specialize in Opioid Addiction Treatment

bhg-logoBehavioral Health Group (BHG) is a leading provider of opioid addiction treatment services with programs presently covering eight U.S. states. BHG provide both maintenance and detox services in an outpatient setting and utilize a variety of FDA-approved medications for the treatment of opioid addiction such as methadone and buprenorphine. Buprenorphine is the active ingredient in Suboxone.

The company currently has 37 treatment center locations in Colorado, Kansas, Kentucky, Louisiana, Missouri, Oklahoma, Tennessee, and Texas. BHG operate in accordance with a number of core values that define their services, to include: character, enthusiasm, compassion, teamwork, and perseverance.

The organization’s website states that they incorporate best practices into their treatment approaches and use outcome-based metrics to consistently improve their service delivery. BHG has achieved full accreditation among their various facilities which means that they meet or exceed quality standards of care as determined by the Joint Commission on Accreditation of Healthcare Facilities.

Medication-assisted treatment is the industry standard for helping those with moderate to severe opioid addictions who have not responded well to traditional forms of therapy. BHG treat both the medical and behavioral aspects of addiction to opioids via medication to alleviate opioid withdrawal symptoms and team-based behavioral counseling used to address a patient’s psychological dependency on opioids.

If you are interested in opioid treatment with BHG, they provide an online inquiry form that you can quickly complete and submit through their website at www.BHGRecovery.com.

For prospective patients living in the San Antonio, Texas community, you can obtain more information on BHG services by visiting the Methadone.US page for San Antonio.

New Opioid Treatment Medication Prepares for Market Release

bunavailSoon to be released is a new oral buprenorphine based product called Bunavail. Bunavail is manufactured by Biodelivery Sciences and is a combination of buprenorphine and naloxone. It is a thin film formulation that is designed to adhere to the inner cheek where it quickly dissolves and is absorbed into the mucosal lining of the mouth.

The medication is touted as delivering about twice as much active ingredient into the patient’s bloodstream compared to sublingual suboxone. Bunavail is scheduled to be released in the third quarter of 2014. A press release by the company mentions that the medication will compete with other products in the $1.7 billion dollar opioid dependency treatment market.

Bunavail is a new advancement in drug delivery technology according to the press release and is reported to produce less constipation than other competing buprenorphine products. Patients can also speak freely while the medication dissolves.

With an estimated 2 million plus people addicted to opioids in the United States, new medication alternatives are welcomed.

Biodelivery Sciences is described as a specialty pharmaceutical company with a focus on pain management and addiction treatment. The company is based out of Raleigh, North Carolina. Bunavail’s FDA approval was announced on June 6, 2014.

Click here for more Information and Articles on Buprenorphine

CRC Health Group to Receive $495,000

feature4bAn article in Maine’s Bangor Daily News outlines a case recently decided in which the Town of Warren, Maine was found to have adopted an ordinance that was ruled discriminatory and in violation of the Americans With Disabilities Act.

CRC Health Group had been fighting to open a methadone clinic in Warren to provide treatment services to those struggling with the disease of opioid addiction. However, the town of Warren had opposed this initiative for several years. U.S. District Court Magistrate Judge John Nivison approved an agreement in which the town of Warren will pay $495,000 to CRC Health Group to drop its lawsuit.

CRC offers a variety of behavioral health treatment programs around the country and has a special focus in opioid addiction services utilizing medication-assisted treatment like methadone and buprenorphine.

Maine has a substantial opiate addiction problem and is in need of more resources for those individuals stuck in the vicious cycle of opiate addiction and withdrawal.

Historically, there have been other similar cases in which town planning boards attempted to oppose the construction of a local methadone clinic. This is commonly referred to as NIMBY (Not In My Back Yard). However, denying people ready access to a needed medical service appears to come with serious financial repercussions.

For More: A Message To The Community